A fundamental analysis of the extreme valuation gap between Market capitalization and net asset value (NAV)In the global financial markets, a lack of liquidity, inefficiencies in the micro-cap sector or simple misunderstandings on the part of investors repeatedly lead to blatant mispricing. However, the extent of the discrepancy that is currently unfolding at Victory Square Technologies (CSE: VST | OTCQX: VSQTF | FSE: 6F6) dwarfs even historical value anomalies. This post summarizes the current status quo (the “now”) as well as the highly effective growth scenario (the “tomorrow”) and calculates the mathematical price potential of the stock.Thanks for reading! Subscribe for free to receive new posts and support my work.1. The “Now”: A Balance Sheet in a State of Absurd UndervaluationCurrently, Victory Square Technologies is valued by the market like an insolvency-prone shell or a passive, unprofitable fund. At a current share price of approx. $0.68, the total market capitalization amounts to just around $71 million. However, this compares to a net asset value (NAV) of $170 million (equivalent to $1.63 per share), conservatively estimated by management. The market is therefore currently granting investors a flat discount of almost 60% on the intrinsic value of the company. The situation becomes particularly absurd when the current NAV is broken down into its individual parts.The listed core stake in the healthcare infrastructure platform Hydreight Technologies alone significantly exceeds VST’s total market capitalization:The conclusion of the status quo: When buying a VST share, investors acquire the liquid Hydreight stake at a whopping discount of over 35% – while the rest of the private portfolio ($40 million), the IP ($14 million) and the cash reserves ($5.2 million) are literally valued at zero by the market.This discount cannot be justified by anything fundamentally. Hydreight is not a speculative concept, but already generated $3.3 million in adjusted EBITDA and $2.6 million in net income in Q1, supported by over 12,000 licenses sold and a network of over 3,000 healthcare professionals in all 50 US states. VST acts as an operational venture builder, whose created infrastructure can be used by new portfolio companies within minutes via plug-and-play, which also earns VST a direct 10% profit share.2. Tomorrow: Dynamic growth and the $9.25 scenarioAnyone who thinks that the upside potential ends at the current NAV of $1.63 is overlooking the inherent scaling power of the portfolio. Hydreight continues to grow rapidly. Analysts put the average price target for Hydreight Technologies shares at $9.25.Since VST holds a firm position of 23.9 million Hydreight shares , any upward movement by the subsidiary will result in massive leverage on Victory Square’s NAV. If Hydreight reaches its fair price target of $9.25, the fundamental reality shifts dramatically:● Future value of Hydreight interest: 23.9 million shares × $9.25 = $221.08 million (an increase of over $112 million from current levels).● VST Total Future NAV: Adding up the remaining portfolio (consistently valued at approximately $61 million), VST’s intrinsic value climbs to an impressive $282.08 million.3. The mathematical price potential calculation in direct comparisonBased on the exact number of approx. 104.22 million VST shares outstanding, there are two highly asymmetric profit scenarios for investors, depending on whether “only” the current discount closes or Hydreight’s growth scenario also occurs:Taking into account the growth scenario (Scenario B), a fair value of around $2.70 per VST share is calculated. Based on the current price level of $0.68, this represents a potential quadrupling of capital (+297.1%).4. Catalysts to release valueTo close this monumental valuation gap in the short to medium term, management has several operational and capital market-specific levers at its disposal:● Share buybacks: At a discount of almost 60%, the buyback of own shares represents the highest-yielding capital allocation. Every dollar repurchased increases the NAV of the remaining shareholders disproportionately.● Spin-Outs & Share Distributions: Through the directDistribution of shares of successful subsidiaries as a dividend in kind to theVST shareholders, the management can securitize the value directly on the stock exchange and pass it on to investors, bypassing the market.● The next generation in the ecosystem: While Hydreight was the validation of the model, the next giants are already waiting in the wings. Insu Therapeutics is revolutionizing the multi-billion dollar market for peptide and GLP-1 injections (weight loss drugs) with a patent-protected buccal platform (oral intake via mucosa). At the same time, Pawsible Ventures is transferring the entire successful Hydreight infrastructure playbook to the booming pet market (”Hydreight for Humans. Pawsible for Pets.”). Conclusion: A countercyclical must-have for value and growth investorsVictory Square Technologies offers fundamental hedging in the "now" through liquid, highly profitable assets that are far above the current market capitalization. In the "Tomorrow", the company ignites by scaling Hydreight to the analyst target of $9.25 as well as the as the launch of new platforms such as Insu and Pawsible. If you are looking for an asymmetric risk profile where the downside is protected by hard assets and the upside offers a potential of around 300%, there is currently no way around VST. Thanks for reading! This post is public so feel free to share it.ShareWhat do you think about the stock? My stock ideas are part of the“Elite Investor Feed” at ☛ Yellobrickthe performance of my stock ideas is tracked, independently of me. At the moment, it looks like this.“Speculative investments are like a tennis match: the decisive factor is to concentrate fully on the next ace instead of being annoyed by the last double fault.” A. GerstenbergerDisclaimerThis text was partly created with AI applications.All content is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities or other financial market instruments. Of course, I try to present the facts to the best of my knowledge and belief, but they can still be false in whole or in part.Therefore, I do not accept any liability for investment decisions that you make on the basis of the information presented here.Conflict of interest: At the time of publication, the author of this publication holds shares/securities of the securities/companies discussed here and intends to sell them depending on the market situation and could benefit in particular from increased trading liquidity. As a result, there is a concrete and clear conflict of interest.